Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers from Harvard University, Cancer Center publish findings in cancer gene therapy
March 31st, 2009
Scientists discuss in 'Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice' new findings in cancer gene therapy. According to recent research from the United States, "hrR3 is an oncolytic herpes simplex virus 1 (HSV-1) mutant that replicates preferentially in tumors compared with normal tissues. Portal venous administration of hrR3 in mice bearing diffuse colorectal carcinoma liver metastases significantly reduces tumor burden and prolongs animal survival." "In this study, we compared survival benefit and biodistribution of hrR3 following intravenous (i.v.) administration versus...
Source: Cancer Weekly (2009-03-31)
|
